Magnesium in Aneurysmal Subarachnoid Haemorrhage - MASH-II
- Conditions
- Aneurysmal subarachnoid haemorrhage
- Registration Number
- EUCTR2006-003523-36-GB
- Lead Sponsor
- etherlands Heart Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
1. Aneurysmal subarachnoid haemorrhage 2. Admission to one of participating hospital within 4 days
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
1. Aged under 18 years 2. Kidney failure (kreatinine > 150 umol/L) 3. Body weight < 50 kg 4. No informed consent obtained
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To assess whether magnesium sulphate reduces the occurrence of poor outcome in patients with an aneurysmal subarachnoid haemorrhage.;Secondary Objective: ;Primary end point(s): 1. Poor outcome 3 months after the haemorrhage assessed by modified Rankin Scale
- Secondary Outcome Measures
Name Time Method